Ignite Creation Date:
2024-05-06 @ 8:01 AM
Last Modification Date:
2024-10-26 @ 11:55 AM
Study NCT ID:
NCT02652455
Status:
COMPLETED
Last Update Posted:
2023-01-19
First Post:
2016-01-08
Brief Title:
Combining PD-1 Blockade CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Pilot Clinical Trial Combining PD-1 Blockade CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Pilot Study is to investigate the safety side effects and benefits of tumor- infiltrating lymphocytes TILs when they are given with the drug nivolumab Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer infection and other diseases
The primary endpoints of this pilot trial will be the safety and feasibility of the treatment regimens
The primary endpoints of this pilot trial will be the safety and feasibility of the treatment regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None